Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status

BACKGROUND: Analysis of deficiency in DNA mismatch repair (dMMR) is currently considered a standard molecular test in all patients with colorectal cancer (CRC) for its implications in screening, prognosis and prediction of benefit from immune checkpoint inhibitors. While the molecular heterogeneity...

Descripción completa

Detalles Bibliográficos
Autores principales: Loupakis, Fotios, Maddalena, Giulia, Depetris, Ilaria, Murgioni, Sabina, Bergamo, Francesca, Dei Tos, Angelo Paolo, Rugge, Massimo, Munari, Giada, Nguyen, Andrew, Szeto, Christopher, Zagonel, Vittorina, Lonardi, Sara, Fassan, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842181/
https://www.ncbi.nlm.nih.gov/pubmed/31703605
http://dx.doi.org/10.1186/s40425-019-0788-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842181/
https://www.ncbi.nlm.nih.gov/pubmed/31703605
http://dx.doi.org/10.1186/s40425-019-0788-5

Ejemplares similares